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Abstract 
Iron deficiency anemia (IDA) is a nutritional disorder that impacts over one billion people 
worldwide, it causes permanent cognitive impairment in children, fatigue in adults, and 
suboptimal outcomes in pregnancy.  IDA can be diagnosed by detection of red blood cells 
(RBCs) that are characteristically small (microcytic) and deficient in hemoglobin (hypochromic), 
typically by examining the results of a complete blood count performed by a hematology 
analyzer.  These instruments are expensive, not portable, and require trained personnel; they are 
therefore, unavailable in many low-resource settings.  This paper describes a low-cost and rapid 
method to diagnose IDA using aqueous multiphase systems (AMPS)—thermodynamically stable 
mixtures of biocompatible polymers and salt that spontaneously form discrete layers having 
sharp steps in density. AMPS are preloaded into a microhematocrit tube and used with a drop of 
blood from a fingerstick. After only two minutes in a low-cost centrifuge, the tests (n = 152) 
were read by eye with a sensitivity of 84% (72-93%) and a specificity of 78% (68-86%), 
corresponding to an area under the curve (AUC) of 0.89. The AMPS test outperforms diagnosis 
by hemoglobin alone (AUC = 0.73) and is comparable to methods used in clinics like 
reticulocyte hemoglobin concentration (AUC = 0.91). Standard machine learning tools were used 
to analyze images of the resulting tests captured by a standard desktop scanner to 1) slightly 
improve diagnosis of IDA—sensitivity of 90% (83-96%) and a specificity of 77% (64-87%), and 
2) predict several important red blood cell parameters, such as mean corpuscular hemoglobin 
concentration. These results suggest that the use of AMPS combined with machine learning 
provides an approach to developing point-of-care hematology.  
 
 
Introduction 
Over one billion people are estimated to suffer from iron deficiency anemia (IDA). As a 
result of depleted iron stores in the body, adults may experience chronic fatigue, among other 
symptoms.1  IDA during pregnancy increases the risk of preterm birth and low birth weight;2 
infants with untreated IDA can have permanent cognitive impairments and delayed physical 
development.3 Iron supplements provide a simple intervention to treat IDA, but the use of iron 
supplements when IDA is not present can result in iron overload.4 The correct diagnosis of IDA 
is important to provide patients with effective care.  While current clinical capabilities can 
effectively diagnose IDA in the developed world, many countries lack the expensive 
instrumentation  necessary to detect IDA, especially at the point-of-care.5   
Red blood indices—measurements of the properties  and numbers of red blood cells—are 
commonly used for the diagnosis of IDA, because they (in contrast to serum iron or ferritin) 
respond quickly to changes in the iron level in the body, and require a less painful and less 
invasive procedure for the patient than the gold standard measurement (iron in bone marrow).6  
Red blood cell indices measured by a complete blood count require a hematology analyzer (a 
flow cytometer, typically with impedance, photometry, and chemical staining capabilities). A 
hematology analyzer, however, is expensive ($20,000-$50,000) and requires highly trained 
personnel and significant technical maintenance. An inexpensive, rapid, and simple method that 
approaches the specificity and sensitivity provided by a hematology analyzer could find 
widespread clinical use. 
An inexpensive tool for the diagnosis of IDA—especially one appropriate for point-of-care 
(POC)—is mainly needed in resource-limited countries where the rate of IDA is often high—
affecting nearly 20% of the population—and where hematology analyzers are only available in 
major hospitals.7  
Identifying microcytic, hypochromic anemia is a potential method to screen for IDA. 
"Anemia" is defined as a condition in which the patient has a low hemoglobin concentration 
(HGB) in the blood.8  Various methods have been developed to diagnose anemia in low-resource 
settings, either by measuring the number of red blood cells (RBCs) per unit volume through spun 
hematocrit (HCT), or by measuring HGB directly. Anemia, both chronic and acute, can, 
however, have many causes, and a diagnosis limited to "anemia" with no further detailed cellular 
and/or molecular description does not necessarily provide enough information for the effective 
treatment of a patient.      
Anemia associated with microcytic (i.e., smaller cells than normal) and hypochromic (i.e., 
lower concentration of hemoglobin per cell than normal)  cells, on the other hand, is mostly a 
result of IDA or thalassemia trait (α or β-thalassemias).9,10 IDA affects  > 10 times more people 
globally than does β-thalassemia trait.7,11,12 Due to the dominance of IDA among other 
conditions causing microcytic, hypochromic (micro/hypo) red blood cells, several studies have 
shown good diagnostic accuracy for IDA by measuring the number of hypochromic red blood 
cells.13–15  Micro/hypo anemias are also associated with a reduction in the mass density of red 
blood cells.16–18 
A tool to distinguish micro/hypo anemia, and thus IDA, quickly from normal blood and other 
forms of anemia would improve the effectiveness of healthcare, and promote a better use of 
resources at the level of primary healthcare, in resource-limited countries. 
Aqueous Multiphase Systems (AMPS) can identify the presence of low density red blood 
cells present in micro/hypo anemia. 
Aqueous multiphase systems (AMPS) are aqueous solutions of polymers and salts that 
spontaneously phase segregate and form discrete, immiscible layers.19–25 Between each phase is 
an interface with a molecularly sharp step in density; these steps can be used to separate 
subpopulations of cells by density. The phases of an AMPS can be tuned to have very small 
differences in density (Δρ < 0.001 g/cm3), can be made biocompatible, are thermodynamically 
stable, and reform if shaken. These properties make AMPS useful for separating cells; the 
stability of these systems removes the need for gentle handling that traditional gradients in 
density require, and makes AMPS particularly well suited for applications in point-of-care 
diagnostics. We previously used AMPS as a tool to enrich reticulocytes from whole blood,26 and 
to detect sickle cell disease.27,28 
Here, we demonstrate the use of AMPS to diagnose IDA, by exploiting the fact that RBCs in 
patients with micro/hypo anemia have lower density than those of healthy patients. Using only a 
drop of blood  (a volume easily obtainable from a finger prick), we can detect, by eye, low 
density RBCs and diagnose IDA in under three minutes; this method had a true positive rate 
(sensitivity) of 84%, with a 95% confidence interval (CI) of 72-93%, and a true negative rate 
(specificity) of 78% (CI = 68-86%).29 
We can slightly improve the diagnostic accuracy of our system by imaging each AMPS test 
with a digital scanner and analyzing the distribution of red color—corresponding to the RBCs—
found in the tube.  Using standard machine learning protocols,30–32 we are able to diagnose IDA 
with a sensitivity of 90% (83-96%) and a specificity of 77% (64-87%), and were able to detect 
hypochromic RBCs above a threshold of 3.9% with a sensitivity of 96% (CI = 88-99%) and a 
specificity of 92% (CI = 84-97%). These results suggest that a simple optical reader paired with 
appropriate algorithms could provide rapid, reader-insensitive diagnosis. 
Interestingly, using machine learning, we can also predict many of the important values 
measured during a complete blood count (namely, values pertaining to red blood cells or "red 
blood cell indices"). Red blood cell indices are used to diagnose many diseases and, therefore, 
predicting their values quickly and simply may be clinically useful.  
Experimental Design 
The sedimentation rate of red blood cells is related to important red-cell indices 
The sedimentation rate of red blood cells through a fluid is a function of several physical 
characteristics of the cells: mass, volume, size, shape, deformability, and density (mass per unit 
volume).  These characteristics are related, directly or indirectly, to a number of red blood cell 
indices, including, mean corpuscular volume (MCV, fL) or the average size of a red blood cell, 
mean corpuscular hemoglobin (MCH, pg/cell) or the average amount of hemoglobin per cell, 
mean corpuscular hemoglobin concentration (MCHC, g/dL) or the average amount of 
hemoglobin per volume of blood, red blood cell distribution width (RDW, %) or the distribution 
in volume of the RBCs. These characteristics, in addition to the hematocrit (HCT)—the ratio of 
the volume of the RBCs to the total volume of blood—can be used to derive the total number of 
RBCs (#RBCs) and the total hemoglobin concentration in the blood (HGB, g/dL). 
Many hematology analyzers use these indices to bin red blood cells.  The percentage of red 
blood cells that are microcytic (%Micro) is defined as the fraction of cells below a specific 
MCV. The percentage of red blood cells that are hypochromic (%Hypo) is defined as the fraction 
of cells below a specific MCHC.  
The hematology analyzer used in this study (ADVIA 2120, Siemens) defines %Micro as the 
percentage of RBCs of MCV < 60 fL and %Hypo as the percentage of RBCs with MCHC < 28 
g/dL. IDA corresponds to a decrease in MCV, MCH, MCHC, and HGB, and an increase in 
RDW, %Hypo, and %Micro.33 Several other hemoglobinopathies have been shown to affect the 
density of RBCs and could affect the performance of a density-based test.  Sickle cell disease,34 
and spherocytosis35 are known to increase the density of some or all of the population of RBCs, 
while β-thalassemia33, α-thalassemia,36 and malaria37 decrease RBC density.   
Classifying Blood Samples Using Hematological Indices  
Here, we discuss several conditions with overlapping population.  Using hematological 
parameters (i.e., red blood cell indices), we define four different states: 1) hypochromia—the 
condition of having hypochromic RBCs— as %hypo ≥ 3.9%, 2) micro/hypo anemia—the 
condition of having hypochromic RBCs and low HGB—as %hypo ≥ 3.9% and when HGB < 
12.0 g/dL for females over 15 yrs, < 13.0 g/dL for males over 15 yrs, < 11.0 g/dL for children 
under 5 yrs, and < 11.5 g/dL for children 5 to 15 yrs,8 3) IDA as micro/hypo anemia when 
%micro/%hypo ≤ 1.5, and 4) β-thalassemia trait for %micro/%hypo > 1.5 .5,13,38 Fig. S1 is a flow 
chart illustrating the classification.  
Designing AMPS to Identify Micro/Hypo RBCs 
AMPS are aqueous buffered mixtures of biocompatible polymers that spontaneous separate 
into thermodynamically stable layers (i.e., phases) possessing distinct densities. We have 
previously demonstrated over 300 AMPS ranging from two to six phases.19 An AMPS with n 
total phases will contain n+1 interfaces (e.g. in a two-phase system: air/top phase, top 
phase/bottom phase, and bottom phase/container).  In order to detect the presence of microcytic 
and hypochromic red blood cells, a properly designed AMPS should: i) have a top layer with 
density greater than that of plasma and its components (≥1.025 g cm-3) in order to minimize 
dilution of the AMPS,39 ii) have a bottom layer less dense than the average red blood cell density 
(which are represented by a Gaussian distribution where mature erythrocytes have a density of 
1.095 g cm-3 and immature erythrocytes (i.e., reticulocytes) of 1.086 g cm-3) such that normal 
blood will pack at the bottom of the tube,40–42 iii) maintain biocompatibility by tuning the pH 
(7.4) and osmolality (290 mOsm/kg) to match  blood,43 and iv) undergo phase separation in a 
short amount of time (≤ 5 minutes) under centrifugation (13,700 g, the typical speed of the 
StatSpin CritSpin centrifuge used in this study).   
We designed a three-phase AMPS (IDA-AMPS) to capture microcytic and hypochromic 
RBCs at two liquid/liquid interfaces, and to provide information about the density distribution of 
the RBCs of a patient. IDA-AMPS contained 10.2% (w/v) poly(vinyl alcohol) (78% hydrolyzed, 
MW ~6 kD—poly(vinyl alcohol) is synthesized by hydrolyzing poly(vinyl acetate) to a certain 
degree, in this case, 78%), 5.6% (w/v) dextran (MW ~500 kD), and 7.4% (w/v) Ficoll (MW 
~400 kD). The density of the phases were ρtop = 1.0505 g cm-3, ρmid = 1.0810 g cm-3, ρbot = 
1.0817 g cm-3 as measured by a U-tube oscillating densitometer (DMA 35, Anton-Paar). 
An AMPS diagnostic can be easy to use, rapid, and fieldable 
We previously demonstrated the use of a point-of-care assay for sickle cell disease using 
AMPS.27,28 A similar strategy is employed here.  Briefly, a plastic microhematocrit tube is 
preloaded with 15 µL of AMPS solution that has been sealed at the bottom with a proprietary 
white sealant (Critoseal, Leica), and centrifuged for 2 minutes at 13,700 g in a hematocrit 
centrifuge (CritSpin, Iris Sample Processing) in order to separate the phases.  
A drop (5 µL) of blood is loaded at the top of the tube through capillary action enabled by a 
small hole in the side of the tube;27 the hole allows the blood to enter the tube up to, but not 
beyond the hole (by capillary wicking).  We previously demonstrated that blood can be loaded 
using this design with a coefficient of variance (CV) in the volume loaded < 4%.28  An 
elastomeric silicone sleeve is then slid over the hole to prevent the blood from leaking during 
centrifugation.  Up to 12 tubes can then be loaded at the same time into the hematocrit centrifuge 
we used and spun for the desired time.  In the current study we used a centrifuge that cost 
~$1,600 (CritSpin, Iris Sample Processing), but our lab has recently transitioned to using a more 
portable centrifuge manufactured by HWLab (Zhejiane Huawei Scientific Instrument Co. LTD, 
www.hwlab.cn) that provides similar performance and costs $155 ($60 each for orders > 400 
units).  The cost of the materials and reagents necessary to fabricate a test at the laboratory scale 
is ~$0.20.27 The total time needed to perform this assay is less than ten minutes (although it can 
be done in as little as three minutes, see Results for more details), and all of the components, 
including a car battery to power the centrifuge, can fit into a backpack (a lead-acid 12V car 
battery is perhaps the best choice because it is widely available, has a long life cycle, is relatively 
low cost, and can be charged by nearly every car and truck in the world as well as by solar 
panels).28 
Results and Discussion 
Visual analysis of IDA-AMPS tests after centrifugation provides a simple diagnostic test for 
micro/hypo anemia 
The diagnostic readout of an IDA-AMPS test is designed for the naked eye to visualize 
the presence or absence of red color above the packed hematocrit at the bottom of the tube. IDA-
AMPS provides three bins of density in which red blood cells can collect: 1) the top/middle 
(T/M) interface (RBCs ≤ 1.081 g cm-3), 2) the middle/bottom (M/B) interface (RBCs > 1.081 g 
cm-3 and ≤ 1.0817 g cm-3), and 3) the bottom/seal (B/S) interface (RBCs ≥ 1.0817 g cm-3) (Fig. 
1A). White blood cells (leukocytes) collect at the T/M interface. In some cases white blood cells 
can agglomerate with RBCs, resulting in a slight red color at the T/M interface, even in a normal 
sample.   
Fig. 1. Design of IDA-AMPS rapid test loaded with blood before and after centrifugation for a 
representative IDA and Normal sample. Blood is loaded into the top of the tube, from a finger 
prick, using capillary action provided by a hole in the side of the tube.  A silicone sleeve is used 
to cover the hole to prevent leakage during centrifugation.  Normal blood packs at the bottom of 
the tube, while less dense RBCs can be seen packing at the interfaces between the phases and 
inside of the phase of the AMPS. Normal and IDA blood can be differentiated, by eye, after only 
2 minutes of centrifugation.  
  
Discarded blood samples were obtained from Children's Hospital Boston (n = 152, see Table 
S2 for a summary of the populations of interest) along with complete blood counts from a 
hematology analyzer (ADVIA 2120, Siemens). For the purpose of understanding the optimum 
timing for a test, the assay was performed by stopping centrifugation every two minutes and 
imaging the tubes using a flatbed scanner (Epson Perfection V330 Photo). After ten minute of 
centrifugation at 13,700 g, nearly all of the RBCs reached their equilibrium positions; at lower 
centrifugation times red color was found throughout the phases of the AMPS in samples having 
micro/hypo RBCs. The time-dependence of the distributions at short centrifugation times 
provides additional information regarding the size and density distribution of red blood cells.  
For this reason—and because a rapid test is desirable—we chose results from t = 2 minutes and 
evaluated the ability of blinded readers to diagnose hypochromia, micro/hypo anemia, and IDA. 
Three readers were trained using a guide comprised of images of tests (Fig. S15) to classify 
the amount of red color above the packed hematocrit (i.e., the redness threshold) as 1) none or 
nearly none, 2) some, 3) moderate, 4) strong, and 5) very strong. In some of the cases, red cells 
were more prevalent at the interfaces, while in others, the red color was highly visible in the 
phases of the AMPS. The guide was available to readers during each reading for reference. An 
average score was determined based on concordance between at least two of the readers. 
Receiver operating characteristic (ROC) curves were generated (Fig. 2) by varying the 
redness threshold (1-5) for the diagnosis of hypochromia, micro/hypo anemia, and IDA. A ROC 
curve is generated by calculating and plotting the true positive rate (sensitivity) versus the false 
positive rate (1 – specificity) at varying threshold values—in this case the redness threshold. The 
area under the curve (AUC) is highest for hypochromia (0.98, CI = 0.96-1.00); the test is  
Fig. 2. Receiver operating characteristic (ROC) curves for (A) hypochromia having different 
threshold values for the percentage of hypochromic red blood cells (%Hypo) and (B) diagnosis 
of hypochromia (%Hypo > 3.9%), micro/hypo anemia, and IDA as determined by visual 
evaluation of the IDA-AMPS test.  Each point of the curve represents the sensitivity and 
specificity of the test for a given redness threshold (1-5) determined by the reader. 
 
 
 
 
excellent at detecting the presence of hypochromic RBCs.  Perfect diagnostic accuracy (i.e., no 
false positives or false negatives) would result in an AUC = 1.00.  The ability to predict 
micro/hypo anemia and IDA for the IDA-AMPS test is lower, with an AUC of 0.89 (CI = 0.83-
0.94) and 0.88 (CI = 0.81-0.94).  For IDA, this corresponds to a sensitivity of 84% (CI = 72-
93%) and a specificity of 78% (CI = 68-86%) at a maximum efficiency cutoff threshold of 
redness > 2 (some red above the packed hematocrit). 
 As a diagnostic for IDA, the performance of IDA-AMPS (AUC = 0.89) exceeds that of 
using only hemoglobin concentration (AUC = 0.73)44 (often the only metric available in low-
resource settings).  The AUC, sensitivity, and specificity of IDA-AMPS is also comparable to 
that of a test for IDA using the reticulocyte hemoglobin concentration (CHr)—a red blood cell 
parameter measured by a hematology analyzer (AUC of 0.91, sensitivity of 93.2% and a 
specificity of 83.2%).45  Although not perfect, this performance for CHr has been high enough to 
gain popularity in clinical use.46 The similar AUC of our test for diagnosing IDA (0.89 vs 0.913) 
suggests that it could be clinically useful as well, especially in LMICs where a hematology 
analyzer is often unavailable.  
We analyzed the concordance between blinded readers and found excellent intra-reader 
agreement for duplicates of the sample blood sample. On average the three readers showed a 
Lin's concordance correlation coefficient, ρc of 0.99 (a ρc of 1.00 is perfect concordance).47  
Inter-reader agreement was slightly lower; we found a ρc of 0.91 between the three readers 
(Table S3). These results suggest that 1) the IDA-AMPS tests are highly reproducible for the 
same samples, and 2) the lower inter-reader agreement may be improved with additional training 
for the readers. 
Digital analysis of IDA-AMPS improves diagnostic performance 
We sought to improve our ability to diagnose IDA, or, at the very least, provide reader-
insensitive and automated method to make this diagnosis, by analyzing the images obtained 
using a flatbed scanner. Digital analysis of the AMPS tests was performed using the following 
steps (Fig. 3): i) a flatbed scanner in transmission mode imaged up to 12 tests simultaneously 
(Epson Perfection V330 Photo), ii) using a custom program written in Python (iPython 
Notebook) individual capillary tubes were detected and cropped, and the tube image was 
converted to hue-saturation-value (HSV) colorspace, iii) the HSV value of each pixel  was 
converted to its corresponding S/V value, and iv) a one dimensional plot of “red intensity” versus 
distance above the (cropped) seal was compiled by summing the S/V values for each row of 
pixels and saved for later analysis.  Further details can be found in the Supporting Information. 
Fig. 4 shows, for a representative normal (A) and IDA (B) sample, i) a scanned test 
image, ii) its corresponding red intensity image where each pixel was converted to S/V, iii) 1-
dimentional red intensity trace, and iv) the first derivative of the 1-dimentional red intensity 
trace.  Digital analysis of images of the IDA-AMPS tests enables the direct comparison of a large 
number of samples.  In Fig. 5, the average red intensity for all normal and micro/hypo samples is 
plotted as a function of distance from the sealed (bottom) end of the tube for different 
centrifugation times; the shaded region represents the 99% confidence intervals.  The red 
intensity is highest at distance = 0 cm where the hematocrit packs at the bottom of the tube (the 
white plastic seal is excluded during analysis and the loading end of the tube is excluded from 
Fig. 5 for clarity). After 2 minutes of centrifugation, the red intensity difference between the 
normal and micro/hypo anemic samples in the majority of the tube is high; most of the red color 
is spread throughout the phases. As the centrifugation time increases, the signal decreases in the  
Fig. 3. Schematic of the method used to analyze the quantity and location of red blood cells in an 
AMPS test using a digital scanner and a custom computer program.   
 
 
 
  
Fig. 4. A) Examples of IDA-AMPS tests after 2 minutes of centrifugation for a representative 
normal and IDA sample. Included is an image of the tube and its corresponding image with 
pixels converted to S/V, 1-D red intensity trace, and the first derivative of the trace. Normal 
RBCs packs at the bottom of the tube, similarly to a hematocrit, while less dense RBCs can be 
seen packing at the interfaces between the phases and inside of the phases of the AMPS. White 
blood cells (leukocytes) pack at the T/M interface and can sometimes agglomerate with RBCs, 
even in normal blood, causing a slight red color at the T/M interface. For clarity the top (loading 
port) of the tubes is not shown.  
 
 Fig. 5. A) Example of micro/hypo sample (laid on its side) after 2 minutes of centrifugation 
and B) red intensity versus distance plots averaged for 152 samples showing discrimination 
between normal (solid blue) and micro/hypo anemic (dashed red) samples at 2, 6, and 10 
minutes centrifugation.   
  
phases and increases at the interfaces as red blood cells reach their equilibrium position based on 
their density.    
Machine learning can diagnose IDA as an alternative to blinded readers 
Machine learning is a powerful approach for finding an efficient way to make predictions or 
decisions from data.31,32 The general problem of predicting classes, or labels, from data is called 
“classification." Here we apply standard machine learning techniques to the classification 
problem of distinguishing micro/hypo anemic samples from normal samples using images of the 
IDA-AMPS test. See the Supporting Information for more details. 
Using the red intensity traces as input data, we trained a machine-learning algorithm (logistic 
regression) to discriminate micro/hypo anemic from normal samples; each sample was given a 
score based on its difference from an average normal sample. Using these scores, receiver 
operating characteristic (ROC) curves were generated for IDA-AMPS for t = 2, 4, 6, 8, and 10 
min by changing the decision threshold for micro/hypo anemia using the assigned score. Fig. 6A 
shows the area under the curve (AUC) values obtained from these ROC curves. The algorithm 
randomly samples from the dataset and optimizes the hyperparameters using a validation set of 
data, and then repeats the process many times. Once the algorithm has been optimized using the 
training and validation data sets, it analyzes the test data set only one time.  For this reason, the 
results for the AUC calculation are presented without error bars.  At short centrifugation times, 
the test provides excellent discrimination for micro/hypo anemia; the AUC for IDA-AMPS 
diminishes after 6 minutes of centrifugation.  These data suggest that the optimum centrifugation 
time for the assay is 2 minutes.   
Using the machine learning algorithm, we are able to distinguish hypochromia from normal 
samples with an AUC of 0.98.  For micro/hypo anemia we found an AUC of 0.93, and for IDA 
we found an AUC of 0.90, corresponding to a sensitivity of 90% (CI = 83-96%) and a specificity 
of 77% (CI = 64-87%) (Fig. 6B).  Table 1 provides a comparison of AUC values for visual and 
digital (machine learning) evaluation of several important subpopulations. These results indicate 
3 things: 1) Both digital and visual analysis are excellent at detecting the presence of 
hypochromic RBCs (i.e. hypochromia). 2) In all cases, the machine learning results are either 
slightly better or similar to visual evaluation. Depending on the use case, this suggests that the 
IDA-AMPS test might be best used alongside a low-cost optical detector (e.g., a desktop 
scanner) or read by the naked eye, with some trade-off between cost and diagnostic accuracy.   3) 
Interestingly, our test is able predict hypochromia, micro/hypo anemia, and IDA in women better 
than men. The AUC for all women in our data set (n = 74) is 0.95 compared to 0.86 for men (n = 
78) and, impressively, is a perfect 1.00 for women ≥ 15 yrs (n = 47).  This difference may be 
because the normal range of HGB and MCV for women is lower than for men and the current 
density of the phases of the AMPS used here is closer to the density of RBCs in female blood.48 
An AMPS with a slightly denser bottom phase density might improve the performance in 
diagnosing the male population (though with a possible tradeoff in performance for women).   
The IDA-AMPS system did not differentiate between IDA and thalassemic traits 
One potential confounding factor for a diagnostic that evaluates the presence of low-
density RBCs is other hemoglobinopathies.  Beta-thalassemia minor (i.e. β-thalassemia trait, β-
TT) and α-thalassemia trait are benign genetic disorders that can present a confounding diagnosis 
to IDA because both conditions result in microcytic and hypochromic red blood cells. 
Identification of thalassemic trait is desired to aid (through genetic counseling) in prevention of 
β-thalassemia major, HbH disease, and Hemoglobin Bart's.10  Several RBC indices have been 
shown to provide discrimination between β-TT  from IDA.49  We were not, however, able to  
Fig. 6. A. Area under the curve (AUC) values for classifying micro/hypo anemia at 2 – 10 
minutes centrifugation time determined by machine learning (n = 152). Perfect diagnostic 
accuracy (compared to classification by a hematology analyzer) would result in an AUC = 1.00.  
For the IDA-AMPS test, the best discrimination between normal and micro/hypo anemic 
samples is, therefore, at 2 or 4 minutes centrifugation.  B. Receiver operating characteristic 
(ROC) curves for diagnosis of hypochromia (%Hypo > 3.9%, solid black line), micro/hypo 
anemia (dashed red line), and IDA (dotted blue line) as determined by machine learning.  
 
 Table 1. Area under the curve (AUC) and 95% confidence interval (CI) results for diagnosing 
hypochromia, micro/hypo anemia, and IDA using visual and digital analysis of the IDA-AMPS 
system after 2 minutes centrifugation.   
 Visual Digital 
 
Hypochromia 
Micro/Hypo 
Anemia 
IDA Hypochromia 
Micro/Hypo 
Anemia 
IDA 
Population 
AUC 
(CI) 
AUC 
(CI) 
AUC 
(CI) 
AUC 
(CI) 
AUC 
(CI) 
AUC 
(CI) 
General 
(n = 152) 
0.98 
(0.96 - 1.00) 
0.89 
(0.83 - 0.94) 
0.88 
(0.81 - 0.94) 
0.98 
 
0.93 
 
0.90 
 
M 
(n = 78) 
0.95 
(0.90 - 1.00) 
0.87 
(0.79 - 0.96) 
0.80 
(0.70 - 0.91) 
0.97 
 
0.91 
 
0.86 
 
F 
(n = 74) 
1.00 
(0.99 - 1.00) 
0.91 
(0.82 - 0.99) 
0.91 
(0.83 - 0.99) 
0.99 
 
0.95 
 
0.95 
 
Age ≥ 15 yrs 
(n = 47) 
0.98 
(0.94 - 1.00) 
0.97 
(0.91 - 1.00) 
0.97 
(0.91 - 1.00) 
1.00 
 
1.00 
 
1.00 
 
Age ≥ 5 yrs, 
< 15 yrs 
(n = 40) 
0.95 
(0.86 - 1.00) 
0.92 
(0.82 - 1.00) 
0.88 
(0.76 - 1.00) 
0.95 
 
0.91 
 
0.91 
 
Age < 5 yrs 
(n = 65) 
0.97 
(0.93 - 1.00) 
0.83 
(0.72 - 0.93) 
0.82 
(0.70 - 0.93) 
0.98 
 
0.86 
 
0.86 
 
 
  
obtain enough β-TT samples to determine the discriminative ability of the test reliably.  Testing 
on a larger population that includes patients with β-TT (and other thalassemias) might be needed 
for our test to be implemented in regions with a high prevalence of β-TT; many Mediterranean 
countries have a prevalence approaching 10%.12 Many countries in Sub-Saharan Africa and parts 
of India, however, have a prevalence of β-TT < 3% and some level of uncertainty in 
differentiating β-TT and IDA might be acceptable.50  
Machine learning can be used to predict red blood cell indices. 
In the process of identifying micro/hypo anemia, we noticed that the characteristic curves of 
red intensity provided an information-rich picture of the dynamics of red blood cells moving 
through AMPS.  The way in which an object moves through an AMPS is related to the density, 
shape, and size of that object.  Many of the parameters measured by a hematology analyzer—so 
called red blood cell indices—should be related to the distribution and movement of red blood 
cells in an AMPS. Given the ability of our machine learning approach to identify micro/hypo 
anemia as well as a trained human user, we tested the ability to use the images of blood moving 
through the IDA-AMPS tests to predict common red blood cell indices.  A rapid and inexpensive 
test that could predict red blood cell indices could have important clinical implications.   
Using standard machine learning techniques for this “regression” problem, we were able to 
predict red blood cell indices from the 1D representation of the output of the IDA-AMPS system 
(see SI for details).30–32 We guarded against over-fitting using repeated random sub-sampling 
validation, in which we randomly sampled a training set and a validation set 500 times, and 
averaged the performance across all validation sets. For each blood parameter we wished to 
predict, we independently repeated our cross-validated training approach. We included blood 
parameters we believed would yield good regression performance (those related to red blood 
cells, %Hypo, HGB) and as negative controls, those that the IDA-AMPS system would not be 
able to detect (those related to colorless cells outside of the density range of our system, WBC, 
PLT). 
True blood parameters, as measured by a hematology analyzer, are compared with predicted 
parameters determined by machine learning in Fig. 7 and Figs. S2-S14. Fig. 7B shows a Bland-
Altman plot for comparing predicted and trust %Hypo. %Hypo showed the best correlation with 
a Pearson's r of 0.94 while the other blood cell indices show a lower correlation. As a 
comparison, other point-of-care tests used to measure HGB (some commercially available) have 
been found to have r = 0.85 - 0.96.51–53 A Pearson’s r of 1.00 would represent perfect correlation 
between the machine learning predictions and the values measured by the hematology analyzer.  
The ability of a machine learning algorithm to predict any variable in a regression problem is 
related to the total size of the data set.  While the number of patients tested here are substantial 
for a prototype POC device, the predictive ability of the algorithm could likely be improved by 
increasing the size of the data set.   
One risk of machine learning is over-fitting. To guard against this we evaluated the tests 
performance for negative controls that should not correlate to images being evaluated (WBC and 
PLT) and found, as expected, a very low correlation (r < 0.2). Owing to the density of the current 
test, the algorithm is also unable to predict %Macro or %Hyper; an AMPS with increased density 
of the phases might instead be used to identify macrocytosis.   
Conclusions 
Using aqueous multiphase systems (AMPS), we have created a simple and low-cost method 
to detect microcytic and hypochromic red blood cells, and hence, IDA.  After two minutes in a  
Fig. 7. A. Machine learning prediction results for %Hypo (Predicted %Hypo) compared to a 
hematology analyzer (True %Hypo) and B. Bland-Altman plot showing good agreement between 
true and predicted %Hypo (n = 152).  In both cases repeated random sub-sampling validation (n 
= 500) was used to guard against over-fitting.   
 
 
  
Table 2. Pearson product-moment correlation coefficient (Pearson's r) for several important 
blood indices demonstrating the predictive ability of the machine learning algorithm using the 
IDA-AMPS test. A Pearson’s r of 1.00 represents perfect positive correlation. As a comparison, 
other point-of-care tests used to measure HGB (some commercially available) have been found 
to have r = 0.85 - 0.96.51–53  
Blood Parameter Pearson's r 
%Hypo 0.94 
MCHC 0.80 
CH 0.80 
HGB 0.78 
HCT 0.76 
MCH 0.73 
RDW 0.71 
HDW 0.68 
%Micro 0.65 
%Micro/%Hypo 0.63 
RBC 0.60 
%Hyper 0.50 
MCV 0.49 
%Macro 0.30 
 
 
 
 
 
 
 
 
 
 
centrifuge that can be powered by battery, the AMPS test can be evaluated, by eye, and used to 
diagnose IDA with an AUC of 0.88.  Using a desktop scanner to image the tests, we evaluate the 
images of the IDA-AMPS tests and use standard machine learning protocols to diagnose IDA 
(AUC = 0.90)—a computer aided diagnosis may be desirable for a fielded device in order to 
reduce possible user variability. The performance of the IDA-AMPS test is comparable to 
previous studies45 using reticulocyte hemoglobin concentration to diagnose IDA (AUC = 0.91) 
and, therefore, may have a high enough performance to find clinical use. 
The WHO estimates that IDA is responsible for ~270,000 deaths and 19.7 million disability-
adjusted life years lost annually.54  Simple interventions, such as oral iron supplements, exist for 
treating IDA.55  Supplements, however, should be used only when a diagnosis is available in 
order to avoid possible side effects. These side effects include iron overload, impaired growth in 
children, and increased risk of severe illness and death in malaria endemic areas.  In developed 
countries, IDA is easily diagnosed in a central laboratory by a complete blood count and 
measurement of serum ferritin concentration. In LMICs, however, a lack of instrumentation, 
trained personnel, and consistent electricity prohibits effective diagnosis. A rapid, low-cost, and 
simple to use platform to diagnose IDA could find widespread use in LMICs.  
To our knowledge, there are currently no direct methods of measuring serum ferritin 
concentration at the POC.  Several methods for measuring hemoglobin—providing a diagnosis 
for anemia, but not necessarily iron deficiency anemia—are available at the POC. These methods 
include: 1) the cyanmethemoglobin method using a photoelectric colorimeter,56 2) 
spectrophotometrically using  the azidemethoglobin method (e.g., the HemoCue system),57 3) 
colorimetrically (both by eye and a smartphone app) using a redox reaction,53 4) paper-based 
devices,58 5) the hematocrit estimate method,59 and 6) the WHO Hemoglobin Color Scale.60  
Since IDA is a nutritional disorder, molecular diagnostics are not useful for diagnosis, except for 
a rare hereditary form of IDA called “iron refractory IDA”.61 
The IDA-AMPS test is able to detect microcytic and hypochromic RBCs and diagnose IDA 
with an AUC comparable to other metrics that have found clinical use, suggesting that it could 
find widespread use as a screening tool for IDA.  In particular, because the equipment needed to 
run the test is portable,28  we expect this method to find use in rural clinics where large fractions 
of the population at risk for IDA, such as children and pregnant women, seek care in LMICs.  
Ultimately, the performance of this test must be validated in such settings to demonstrate 
feasibility of using and interpreting the assay.   
Using machine learning analysis of digital images, we demonstrate an algorithm that is as 
good as visual interpretation at identifying IDA; the algorithm determined by the machine 
learning can be readily implemented into a smartphone application (app). Mobile health—or 
mHealth, the general term given to portable technologies used to diagnose disease that can 
transmit data over mobile phone networks—is becoming increasingly widespread in Sub-
Saharan Africa.62,63 By integrating algorithms determined by machine learning into a smartphone 
app—eliminating the need for visual interpretation and potential bias from users—our test might 
be used by minimally trained healthcare workers in LMICs.  Interestingly, this test may also find 
use in veterinary medicine.  IDA in livestock, especially pigs, is increasingly common due to 
modern rearing facilities that eliminate the animals’ exposure to iron-containing soil; IDA in pigs 
can cause weight loss, retarded growth, and an increased susceptibility to infection.64   
A simple method to perform a complete blood count without the need to draw large volumes 
of blood and send that sample to a central laboratory—so called, point-of-care hematology—has 
been a major goal of the diagnostic community for several decades.  We use machine learning to 
analyze images of IDA-AMPS tests to predict several red blood cell indices, a first step towards 
POC hematology. We find, in the best case, a Pearson’s r of 0.94 for predicting the number of 
hypochromic RBCs (%Hypo). HemoCue, the most widely used portable test used to measure 
hemoglobin concentration, in comparison, has been shown to correlate nearly perfectly with a 
hematology analyzer (Pearson’s r = 0.99) when operated by trained laboratory staff. When the 
device was used by clinical staff, however, the correlation was much poorer (Pearson’s r = 0.66). 
65 The lessons from this study suggest that a POC hematology system needs to be designed to be 
as simple as possible to operate.  
The IDA-AMPS test is a new approach to diagnosing IDA and, using machine learning 
algorithms, to predict red blood cell indices. Instead of directly measuring a biological marker 
such as concentration of hemoglobin or serum ferritin, our method relies on observing the way in 
which red blood cells move through a viscous media (a function of their density as well as size 
and shape) to make a diagnosis.  In the future, this approach may be applied to other diseases or 
biological applications.    
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